Research Article

Trend in Childhood Mortality After Pneumococcal Conjugate Vaccine (PCV-13) and Rotavirus Vaccines Introduction in the Nouna Health and Demographic Surveillance System, Burkina Faso

Mamadou Bountogo[1,2]*, Eric Nebié[1,5,7], S Pascal Zabré[1], Seraphin Simboro[1], Ali Sié[1,3,4], Nicolas Meda[2] and Edouard Betsem[6]

[1]Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso, Africa

[2]Université Joseph Ki-Zerbo, Ouagadougou, Burkina Faso, Africa

[3]Heidelberg University, Heidelberg, Germany

[4]Proctor Foundation, University of California San Francisco, San Francisco, USA

[5]Swiss Tropical and Public Health Institute, Allschwil, Switzerland

[6]Faculty of Medicine and Biomedical Sciences, Yaounde, Cameroun

[7]University of Basel, Switzerland

*Corresponding Author: Mamadou Bountogo, Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso, Africa.

Abstract

Background: Pneumonia and diarrhea remain two leading causes of children under 5 years mortality. PCV-13 vaccine and rotavirus vaccine were introduced into the Burkina Faso EPI in 2013. Given the diversity of circulating serotypes and vaccine schedules, the WHO recommended an evaluation of their actual effectiveness after their introduction in different countries. This study, using an interrupted time series analysis, proposes to evaluate the effectiveness of PCV-13 and rotavirus vaccine on under 5 years mortality.

Methods: The study used interrupted time series designs with a pre-intervention period from 2009-2013 and a post-intervention period from 2014 to 2015. The monthly mortality rate ratio was the variable of interest. A generalized linear model was applied using log-transformed mortality rates as outcomes, with a Poisson distribution, adjusted.

Results: The infant mortality rate ratio was 0.84 (95% CI = 0.58-1.22, p = 0.37) 0.90 (95% CI = 0.70-1.15, p = 0.43), 0.84 (95% CI = 0.68;1.02, p = 0.09) on children aged 0-59 months, 0-11 months, 12-59 months, respectively. Although not statistically significant, the results in this study showed a 16% decrease in mortality in children aged 0-59 months

Conclusions: A positive effect of the newly introduced rotavirus and 13-valent pneumococcal conjugated vaccine was observed in the current study and needs to be consolidated in a bigger population size.

Keywords: Childhood Mortality; Trend; Nouna HDSS; PCV-13; Rotavirus Vaccines

Abbreviations

EPI: Expanded Program on Immunization; HDSS: Heath and Demographic Surveillance System; PCV: Pneumococcal Conjugate Vaccine; WHO: World Health Organization

Introduction

Diarrhea and pneumonia are the two leading causes of children of post-neonate mortality in 2019 worldwide. Annual analysis of global mortality data from 2000 to 2019 shows that sub-Saharan

Trend in Childhood Mortality After Pneumococcal Conjugate Vaccine (PCV-13) and Rotavirus Vaccines Introduction in the Nouna Health and Demographic Surveillance System, Burkina Faso

16

Africa and Southeast Asia remain the largest contributors to under-five deaths [1] For this reason, the World Health Organization (WHO) and the Global Alliance for Vaccines and Immunization (GAVI) have encouraged and supported the introduction of pneumococcal conjugate and rotavirus vaccines in national expanded programs on immunization (EPI) in resource limited countries [2,3]. Several clinical trials have shown that pneumococcal conjugate vaccines are 12-50% effective in preventing invasive pneumococcal diseases caused by vaccine preventable serotypes [4-7]. Conjugate vaccines have effect on carriage of vaccine strains in vaccinated individuals breaking the human-to-human chain of transmission [8-10]. This protection known as herd or collective immunity depicts a more enhanced effect of the conjugate pneumococcal vaccine in countries with limited resources such as Burkina Faso. The replacement of circulating serotypes with emerging non-vaccine serotypes thus contributes to the reduction of the potential benefits of this vaccination [11,12]. Rotavirus is the leading cause of severe infectious diarrhea in children in developing countries [13-15]. Effective rotavirus vaccines have been developed in recent years and introduced into national expanded programs of immunization in SSA [16,17].

Rotavirus and conjugated pneumococcal vaccines were introduced in Burkina Faso late December 2013. Both vaccines are administered concurrently with pentavalent vaccine at 2, 3, and 4 months of life. The WHO recommended a post introduction assessment of these vaccines' schedules and effectiveness on circulating serotypes [18,19]. Most of the impact studies carried out are hospital-based data [20,21]. In low incomes countries, more than 75% of deaths occur in the community and are not documented by health services according to Nouna HDSS 2010 data [22]. The current impact assessment of PCV and rotavirus vaccines in children under five years mortality in a rural population and health surveillance system in Burkina Faso aims to bridge this gap.

Materials and Methods

Study site

This study was carried out in the Nouna Health, and Demographic Surveillance System (HDSS) operated by the *Centre de Recherche en Santé de Nouna* (CRSN) in rural Burkina Faso (Figure 1). The population is approximately 100,000 inhabitants in 15 000 households across 58 villages and the town of Nouna in 2020. The

CRSN conducts longitudinal monitoring of vital events as well as cross-sectional surveys in households [23]. During households' visits, the interviewers regularly update the demographic data and vital events (death, birth…) that have occurred since the previous visit.


Figure 1: Nouna HDSS map.

Study design

The ITS was used in our study to evaluate the both the two vaccines (PCV-13 and rotavirus vaccine) effectiveness on child mortality in Nouna-HDSS. The ITS is a precious study design for evaluating the effectiveness of population-level health interventions [24]. ITS, sometimes called quasi-experimental time series analysis, is a method of statistical analysis involving the tracking of a long-term period before and after an intervention point to assess the effects of the intervention

Study population

Children aged 0 to 59 months who are permanent residents of the Nouna HDSS were enrolled in this study.

Trend in Childhood Mortality After Pneumococcal Conjugate Vaccine (PCV-13) and Rotavirus Vaccines Introduction in the Nouna Health and Demographic Surveillance System, Burkina Faso

17

Statistical analysis

In this study, the two variables of interest are death (dependent variable) and the introduction of PCV-13 and rotavirus vaccines. Verbal autopsies which are methods of determining causes of deaths is used to diagnose the causes of death using the primary data collected on signs and symptom of the deceased persons. The Inter-VA was used to determine the causes of death. This software has shown low sensitivity to determining infectious causes such as pneumonia and diarrhea [25-27]. That is why we only looked at all-cause mortality in this study. For the introduction of the two vaccines, the variable is set to 1 after 2013 and 0 from 2009 to 2013.

The database with demographic was transformed according to the longitudinal procedures of INDEPTH [28,29] to allow a time series analysis. The variable date of the events was very important to allow the periodization in months to years for the calculation of the different indicators. Monthly mortality counts and mortality rates were used as the outcomes of interest. The analysis was initially descriptive and a measure of the pre- and post-introduction trends of the two vaccines was carried out. The pre-introduction period ranged from 1 January 2009 through 31 December 2013 and the post-introduction period ranged from January 1st, 2014 through December 31st, 2015. We did a segmented regression to model the mortality rate. The monthly mortality rate was converted to logarithm and an adjusted Poisson model was used considering over-dispersion and seasonality.

We applied a generalized linear model using logarithm transformed mortality rates as results, with a Poisson distribution, adjusted accordingly to account for dispersion. The Breusch-Godfrey autocorrelation test was used. The efficacy of the two vaccines on infant and juvenile mortality was calculated as the mortality rate ratio (MRR) from the model. All statistical analyses were performed using STATA software (version 14). The significance threshold of 5% was considered.

Results and Discussion

Results

During the 6-year study period, the Nouna-HDSS recorded 1954 deaths in under five-year children, of which 1358 (2009 to 2013) occurred before vaccines introduction in the Expanded Program on Immunization (EPI) and 596 from 2014 to 2015 after vaccines introduction in EPI. The lowest number of deaths was recorded in the month of June (n = 84 over 6 years) and the highest in August (n = 288 over 6 years). The year 2009 and 2013 recorded the lowest number of death while 2012 recorded the highest number followed by 2015. Deaths in children under one year accounted for 25% of all deaths in children under 5 years (Table 1).

Year	Death	
	N	%
2009	220	11.26
2010	262	13.41
2011	315	16.12
2012	341	17.45
2013	220	11.26
2014	276	14.12
2015	320	16.38
Month		
Jan	137	7.01
Feb	151	7.73
Mar	123	6.29
Apr	110	5.63
May	95	4.86
Jun	83	4.25
Jul	107	5.48
Aug	288	14.74
Sept	281	14.38
Oct	183	9.37
Nov	214	10.95
Dec	182	9.31
Age		
0-11month	506	25.90
12-59month	1448	74.10
Season		
Dry	1012	51.79
Raining	942	48.21
Seasonal monthly average		
Dry	144.57	-
Raining	188.40	-

Table 1: Under five-year death repartition in Nouna-HDSS from 2009 to 2015, Burkina Faso.

Trend in Childhood Mortality After Pneumococcal Conjugate Vaccine (PCV-13) and Rotavirus Vaccines Introduction in the Nouna Health and Demographic Surveillance System, Burkina Faso

18

The infant-juvenile mortality ratio was 0.84 (95% CI = 0.58-1.22, p = 0.37) in children 0-59 months of age. The mortality ratio for children under 1 year of age and was 0.90 (95%CI = 0.70-1.15, p = 43) and those aged 12-59 months 0.84 (95%CI = 0.68-1.02, p = 0.09) (Table 2 and Figure 2).

Age	MRR*Vaccines introduction (95% CI)	Vaccine effectiveness (95% CI)	P-value
0-59 Months	0.84(0.58 to 1.22	16% (-22;42)	0.37
0-11 Months	0.90(0.70: 1.15)	10% (-15;30)	0.43
12-59 Months	0.84(0.68;1.02)	16% (-2;32)	0.09

Table 2: Efficacy of the introduction of the two vaccines (VPC13 and rotavirus) on under five-year children mortality, 2009-2015, in Burkina Faso.

MRR* mortality rate ratio.

Figure 2: Evolution of the infant-juvenile mortality rate ratio 2009-2015 Nouna H-DSS.

a: Evolution of 0-59-month mortality rate ratio 2009-2015 in Nouna H-DSS.

b: Evolution of 0-11-month mortality rate ratio 2009-2015 in Nouna H-DSS.

c: Evolution of 12-59-month mortality rate ratio 2009-2015 in Nouna H-DSS.

Discussion

Two years after the introduction of PCV-13 and Rotavirus vaccines into the national EPI, the impact of these vaccines seems low in Nouna area for all-cause under-five years mortality. In other studies, elsewhere, significant effect has been shown for pneumococcal conjugate vaccine on the reduction of hospitalizations for pneumonia [21,30-35] and invasive pneumococcal diseases (inva-sive pneumonia, sepsis, pneumococcal meningitis) after introduction of PCV13 vaccine [36,37]. The reduction of diarrhea-related deaths has been observed after introduction of rotavirus vaccine [16,38]. Our data describe a 16% decrease in all-cause under-five years mortality but did not identify a significant PCV-13 and rotavirus vaccine effect on all-cause mortality in children under-five years as seen elsewhere with pneumococcal vaccine and reduction of hospitalizations for pneumonia [32,35,39]. Studies have shown a reduction in all-cause mortality of up to 10% with rotavirus vaccine in children under five years [38,40]. In Malawi where rotavirus vaccine was introduced 2 years after pneumococcal vaccine, a combined 34% vaccine effectiveness was described in the same age group [41].

The use of overall under-five mortality as an endpoint to measure the impact of PCV requires sufficiently similar protocols and data pooling from several countries with high infant and child mortality [18]. Of all possible explanations of the limited impact of both vaccines in our study, the low sample size could be one of those explanation. Other factors could have impacted negatively such as malaria which is a major mortality driver [42] and vaccine coverage. Suarez., *et al.* [43] in a study conducted in Peru which showed that PCV-13 was not effective in reducing mortality in children under 1 year of age when vaccination coverage was below 85%. Based on the study from Kabore., *et al.* [44] which found a vaccine coverage of 74% in children under 5 years of age in Burkina Faso in 2015, we hypothesize that vaccine coverage was lower than 85% in our study area.

There are some limitations to our study. The interrupted time series compare the evolution of a health phenomenon before and after an intervention that would alter the natural evolution of this health phenomenon [24,45]. Our study looked at all-cause mortality, which is multifactorial. Some interventions or natural phenomena can influence infant-child mortality (introduction of other vaccines, epidemics, other endemic diseases, other public health interventions).

Conclusion

Our study show that PCV-13 and Rotavirus vaccines were not found to achieve their targeted impact on mortality reduction in children aged 0-59 months. It is likely that the health system was not sufficiently prepared for these introductions and other possi-

Trend in Childhood Mortality After Pneumococcal Conjugate Vaccine (PCV-13) and Rotavirus Vaccines Introduction in the Nouna Health and Demographic Surveillance System, Burkina Faso

19

bly combined factors. among which an increased malaria mortality, pneumococcus serotype replacement, all-cause mortality, and possible programmatic or vaccine shortage issues such as the Rotavirus vaccine shortage in April-May 2014 might have play a role. However, a reduction trend on mortality was observed in children aged 12-59 months suggestive of possible effectiveness of both vaccines on overall child mortality.

Acknowledgements

Conflict of Interest

No conflict of interest in this work. Neither the author nor any member of his family or relationship is a shareholder or employee of the pharmaceutical companies that manufacture these two vaccines.

Bibliography

1. GBD. "Under-5 Mortality Collaborators. Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019". *Lancet (London, England)* 398.10303 (2021): 870-905.

2. WHO. Strategic Advisory Group of Experts WHO. "Meeting of the immunization Strategic Advisory Group of Experts, November 2006-conclusions and recommendations". *The Weekly Epidemiological Record* 82.1 (2007): 16.

3. WHO. Strategic Advisory Group of Experts WHO. "Meeting of the immunization Strategic Advisory Group of Experts, April 2009-conclusions and recommendations". *The Weekly Epidemiological Record* 84 (2009): 213-236.

4. Gomez JA., *et al*. "Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru". *BMC Public Health* 13.1 (2013): 1025.

5. Principi N., *et al*. "Prevention of Community-Acquired Pneumonia with Available Pneumococcal Vaccines". *International Journal of Molecular Sciences* 18.1 (2016): 30.

6. Cafiero-Fonseca ET., *et al*. "The full benefits of adult pneumococcal vaccination: A systematic review". Borrow R, éditeur". *PLOS ONE* 12.10 (2017): e0186903.

7. Torres A., *et al*. "Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?" *European Journal of Clinical Microbiology and Infectious Diseases* 34.1 (2015): 19-31.

8. Robinson JL. "Mise à jour sur la vaccination contre la méningococcie invasive chez les enfants et les adolescents canadiens". *Paediatrics and Child Health* 23.1 (2018): e5-9.

9. Cohen R., *et al*. "Dynamic of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 introduction in France". *Vaccine* 28.37 (2010): 6114-6121.

10. Léophonte P., *et al*. "Rencontres et échanges sur les pathologies infectieuses respiratoires". *Libbey Eurotext* (1995).

11. Singleton RJ., *et al*. "Invasive Pneumococcal Disease Caused by Nonvaccine Serotypes Among Alaska Native Children with High Levels of 7-Valent Pneumococcal Conjugate Vaccine Coverage". *JAMA* 297.16 (2007): 1784.

12. Pichon B., *et al*. "Changes in Molecular Epidemiology of Streptococcus pneumoniae Causing Meningitis following Introduction of Pneumococcal Conjugate Vaccination in England and Wales". *Journal of Clinical Microbiology* 51.3 (2013): 820-827.

13. Groupe de travail scientifique de l'OMS. "Diarrhées à rotavirus et autres diarrhées virales". *Bulletin of the World Health Organization* 4.58 (1980): 539-557.

14. Sangaji MK., *et al*. "Etude épidémio-clinique des diarrhées aiguës à rotavirus chez les nourrissons à l'hôpital Jason Sendwe de Lubumbashi, République Démocratique du Congo". *The Pan African Medical Journal* (2015).

15. Senecal J. "Diarrhea in children in French West Africa". *Bulletin of the World Health Organization* 21 (1959): 321-336.

16. Soares-Weiser K., *et al*. "Vaccines for preventing rotavirus diarrhoea: vaccines in use". *Cochrane Database of Systematic Reviews* 3 (2019): CD008521.

17. Steele AD., *et al*. "Experiences with rotavirus vaccines: can we improve rotavirus vaccine impact in developing countries?" *Human Vaccines and Immunotherapeutics* 15.6 (2019): 1215-1227.

Trend in Childhood Mortality After Pneumococcal Conjugate Vaccine (PCV-13) and Rotavirus Vaccines Introduction in the Nouna Health and Demographic Surveillance System, Burkina Faso

20

18. OMS. "Mesurer l'impact de la vaccination par les vaccins conjugués anti-Streptococcus pneumoniae et anti-Haemophilus influenzae type b». Programme élargi de vaccination (PEV) du Département Vaccination, Vaccins et Produits biologiques (2013).

19. Sartori AMC., *et al*. "Methods and challenges for the health impact assessment of vaccination programs in Latin America". *Revista de Saúde Pública* (2015).

20. Faye PM., *et al*. "Impact of 13-Valent Pneumococcal Conjugate Vaccine on Meningitis and Pneumonia Hospitalizations in Children aged < 5 Years in Senegal, 2010-2016". *Clinical Infectious Diseases* 69.2 (2019): S66-71.

21. Kaboré L., *et al*. "Impact of 13-valent pneumococcal conjugate vaccine on the incidence of hospitalizations for all-cause pneumonia among children aged less than 5 years in Burkina Faso: An interrupted time-series analysis". *International Journal of Infectious Diseases* 96 (2020): 31-38.

22. Yé M., *et al*. "An improved method for physician-certified verbal autopsy reduces the rate of discrepancy: experiences in the Nouna Health and Demographic Surveillance Site (NHDSS), Burkina Faso". *Population Health Metrics* 9.1 (2011): 34.

23. Sié A., *et al*. "The Health and Demographic Surveillance System (HDSS) in Nouna, Burkina Faso, 1993-2007". *Global Health Action* 3.1 (2010): 5284.

24. Lopez Bernal J., *et al*. "Interrupted time series regression for the evaluation of public health interventions: a tutorial". *International Journal of Epidemiology* (2016): dyw098.

25. Setel PW., *et al*. "Validity of verbal autopsy procedures for determining cause of death in Tanzania". *Tropical Medicine and International Health* 11.5 (2006): 681-696.

26. Chandramohan D., *et al*. "Effect of misclassification of causes of death in verbal autopsy: can it be adjusted?" *International Journal of Epidemiology* 30.3 (2001): 509-514.

27. Maude G. "The effect of different sensitivity, specificity and cause-specific mortality fractions on the estimation of differences in cause-specific mortality rates in children from studies using verbal autopsies". *International Journal of Epidemiology* 26.5 (1997): 1097-1106.

28. Vermunt JK., *et al*. Event History Analysis. In: Everitt BS, Howell DC, éditeurs. "Encyclopedia of Statistics in Behavioral Science". Chichester, UK: John Wiley and Sons, Ltd (2005).

29. Bocquier P., *et al*. "A training manual for event history data management using Health and Demographic Surveillance System data". *BMC Research Notes* 10.1 (2017): 224.

30. Silaba M., *et al*. "Effect of 10-valent pneumococcal conjugate vaccine on the incidence of radiologically-confirmed pneumonia and clinically-defined pneumonia in Kenyan children: an interrupted time-series analysis". *Lancet Global Health* 7.3 (2019): e337-346.

31. Diaz J., *et al*. "Effectiveness of the 10-Valent Pneumococcal Conjugate Vaccine (PCV-10) in Children in Chile: A Nested Case-Control Study Using Nationwide Pneumonia Morbidity and Mortality Surveillance Data". Melo-Cristino J, éditeur". *Plos One* 11.4 (2016): e0153141.

32. Eskola J., *et al*. "Efficacy of a Pneumococcal Conjugate Vaccine against Acute Otitis Media". *The New England Journal of Medicine* 344.6 (2001): 403-409.

33. Mackenzie GA., *et al*. "Efficacy of different pneumococcal conjugate vaccine schedules against pneumonia, hospitalisation, and mortality: Re-analysis of a randomised trial in The Gambia". *Vaccine* 32.21 (2014): 2493-500.

34. Cutts F., *et al*. "Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial". *The Lancet* 365.9465 (2005): 1139-1146.

35. Lucero MG., *et al*. "Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age". Cochrane Acute Respiratory Infections Group, éditeur". *Cochrane Database Systematic Review* (2009).

36. Wahl B., *et al*. "Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15". *Lancet Global Health* 6.7 (2018): e744-757.

37. Kularatna S., *et al*. "Burden of invasive pneumococcal disease (IPD) in Sri-Lanka: Deriving a reasonable measure for vac-

Trend in Childhood Mortality After Pneumococcal Conjugate Vaccine (PCV-13) and Rotavirus Vaccines Introduction in the Nouna Health and Demographic Surveillance System, Burkina Faso

21

cine introduction decision making". *Vaccine* 33.27 (2015): 3122-3128.

38. Debellut F., *et al*. "Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study." *Lancet Global Health* 7.12 (2019): e1664-1674.

39. Kilpi T., *et al*. "Protective Efficacy of a Second Pneumococcal Conjugate Vaccine against Pneumococcal Acute Otitis Media in Infants and Children: Randomized, Controlled Trial of a 7-Valent Pneumococcal Polysaccharide-Meningococcal Outer Membrane Protein Complex Conjugate Vaccine in 1666 Children". *Clinical Infectious Diseases* 37.9 (2003): 1155-1164.

40. Atherly D., *et al*. "Rotavirus Vaccination: Cost-Effectiveness and Impact on Child Mortality in Developing Countries". *The Journal of Infectious Diseases* 200.s1 (2009): S28-38.

41. Bar-Zeev N., *et al*. "Population Impact and Effectiveness of Monovalent Rotavirus Vaccination in Urban Malawian Children 3 Years After Vaccine Introduction: Ecological and Case-Control Analyses". *Clinical Infectious Diseases* 62.2 (2016): S213-219.

42. World_Malaria_Report (2020).

1. Suarez V., *et al*. "Impact of pneumococcal conjugate vaccine in children morbidity and mortality in Peru: Time series analyses". *Vaccine* 34.39 (2016): 4738-4743.

43. Kaboré L., *et al*. "Pneumococcal Carriage in Burkina Faso After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Results From 2 Cross-sectional Population-Based Surveys". *The Journal of Infectious Diseases* 224.12-2 (2021): S258-266.

44. Wagner AK., *et al*. "Segmented regression analysis of interrupted time series studies in medication use research". *Journal of Clinical Pharmacy and Therapeutics* 27.4 (2002): 299-309.

Volume 5 Issue 9 September 2022